DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening and Drug Repositioning Insights

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 clinically approved bioactive compounds, all supplied at 10 mM in DMSO for rapid deployment in HTS and HCS workflows (product details). Each compound is validated by major agencies (FDA, EMA, HMA, CFDA, PMDA) or listed in pharmacopeias. The library covers a broad array of mechanisms including receptor modulation, enzyme inhibition, and ion channel regulation. It supports drug repositioning and novel target identification, as demonstrated in studies like the identification of valsartan as a SUGCT inhibitor (Lazarus et al. 2024). The ready-to-use format ensures stability for 12–24 months and compatibility with 96-well and deep-well plate formats, supporting reproducibility across research fields.

Biological Rationale

The DiscoveryProbe™ FDA-approved Drug Library addresses the need for rapid, systematic evaluation of clinically relevant compounds in biomedical research. Drug repositioning leverages existing safety and pharmacokinetic profiles to accelerate therapy discovery (see prior review; this article extends mechanistic context beyond the prior overview). FDA-approved compounds are prioritized due to their well-characterized human safety data, facilitating translational studies and lowering regulatory barriers (DiscoveryProbe™ FDA-approved Drug Library). Disease models such as cancer and neurodegeneration benefit from mechanistic diversity, as multiple pathways are implicated in disease progression. The inclusion of compounds like doxorubicin (anticancer), metformin (metabolic), and atorvastatin (lipid regulator) enables hypothesis-driven screens for unexpected target interactions or off-label efficacy. Recent advances, such as the identification of valsartan as a SUGCT inhibitor in glutaric aciduria type 1 (GA1) research, highlight the utility of approved compound collections for rare disease target validation (Lazarus et al., 2024).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This library encompasses compounds across multiple mechanistic classes:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear receptors, and ion channels.
• Enzyme inhibitors: Including kinases, proteases, and transferases (e.g., valsartan as a SUGCT inhibitor).
• Ion channel modulators: Affecting voltage-gated and ligand-gated channels.
• Signal pathway regulators: Modulating key signaling cascades in cell growth and apoptosis.

Each compound’s mechanism is annotated based on regulatory filings, pharmacopeia data, and peer-reviewed literature. For example, doxorubicin is a topoisomerase II inhibitor used in oncology, while metformin activates AMP-activated protein kinase (AMPK), modulating cellular metabolism. The library enables unbiased phenotypic screening and focused target-based assays, as validated in high-throughput settings (see format/throughput discussion; this article details mechanistic annotation and stability data).

Evidence & Benchmarks

• Contains 2,320 unique compounds, all approved by at least one major regulatory agency (FDA, EMA, HMA, CFDA, or PMDA) or listed in pharmacopeias (catalog).
• Compounds are supplied as 10 mM DMSO solutions, stable for 12 months at -20°C and 24 months at -80°C (manufacturer stability data, product page).
• Identified valsartan and losartan carboxylic acid as inhibitors of SUGCT using HTS with this library, supporting rare disease target discovery (Lazarus et al., 2024).
• Optimized for both high-throughput screening (HTS) and high-content screening (HCS), with formats including 96-well and deep-well plates, and 2D barcoded tubes (see format/benchmarking—this article provides updated stability and mechanistic annotations).
• Used in translational and mechanistic studies spanning oncology, neurodegeneration, and metabolic disorders (see application case studies; this article updates oncology focus with new rare disease data).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for:

• High-throughput screening (HTS) for new indications of existing drugs.
• High-content screening (HCS) to analyze complex cellular phenotypes.
• Drug repositioning, leveraging known pharmacokinetics and toxicology profiles.
• Target validation in disease models, including rare and metabolic diseases.
• Mechanistic dissection of signaling pathways and protein targets.

However, users should be aware of certain boundaries.

Common Pitfalls or Misconceptions

• Not all compounds are selective; many have polypharmacology, leading to off-target effects.
• The library is not suitable for de novo drug discovery; all compounds are previously approved or characterized.
• Biological outcomes depend on cell type, assay conditions, and compound solubility; DMSO tolerance must be empirically determined.
• Use in in vivo models requires additional formulation and pharmacokinetic considerations.
• Regulatory status may vary by region; not all compounds are globally approved.

Workflow Integration & Parameters

The library is provided in ready-to-use 10 mM DMSO stock solutions, compatible with multi-channel pipetting and automated liquid handling. Shipping is on blue ice for evaluation sizes and at room temperature or blue ice for larger lots. Compounds are formatted for 96-well plates, deep-well plates, or 2D barcoded tubes, supporting integration with robotic platforms. Stability is maintained for 12 months at -20°C and 24 months at -80°C. Each vial or well is traceable via barcode. Researchers should validate DMSO tolerance in their assay system (typically ≤0.1% DMSO final concentration is tolerated in cell-based assays). Reproducibility is enhanced by controlling for plate layout, edge effects, and freeze-thaw cycles. For more on HTS/HCS integration, see this prior article (this article details new stability and rare disease screening data).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a rigorously curated, stable, and mechanistically diverse resource for high-throughput and high-content screening. Its utility is highlighted by both translational applications (e.g., oncology, neurodegeneration) and emerging rare disease target discovery, as in the identification of SUGCT inhibitors. As biomedical research increasingly prioritizes drug repositioning and rapid target validation, this library provides a reproducible, regulatory-anchored platform for accelerating therapeutic innovation (Learn more).